Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Posted 12 months ago Tagged

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]

Michael Kades, Director, Competition Policy, Washington Center for Equitable Growth

#76 What’s Ahead in Pharmaceutical Antitrust Enforcement? Taking Stock of Key Pharmaceutical Issues and Enforcement Actions

Posted 3 years ago Tagged

Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]